Clinical Trials Sponsored by SHANGHAI RONA Therapeutics Co.,Ltd.

Total 1270 results

Ikaria Bioscience Pty Ltd
SHANGHAI RONA Therapeutics Co.,Ltd.

Not yet recruiting

the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C

To Reduce the LDL-C Level in Hypercholesteremia Patients
Ocumension Therapeutics (Shanghai) Co., Ltd

Completed

Study of OT202 in Treating Moderate to Severe Dry Eye

Dry Eye

China
Shanghai OriginCell Therapeutics Co., Ltd.

Not yet recruiting

An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung
Cutia Therapeutics (Shanghai) Co., Ltd

Completed

To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris

Acne Vulgaris

China
Ocumension Therapeutics (Shanghai) Co., Ltd

Completed

Study of Dexycu in Treating Intraocular Inflammation

Inflammation | Cataract

China
Changhai Hospital
Shanghai Ultra-T Immune Therapeutics Co. LTD

Not yet recruiting

A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System

Digestive Tumor
Asia Cell Therapeutics (Shanghai) Co., Ltd.

Not yet recruiting

Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis

Decompensated Liver Cirrhosis
Asia Cell Therapeutics (Shanghai) Co., Ltd.

Not yet recruiting

Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Zhongshan Hospital

Recruiting

A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Sarcoma | Breast Cancer | Gastric Cancer | Ovarian Cancer | Solid Tumor

China
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Zhongshan Hospital

Recruiting

CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas

SAR

China
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Zhongshan Hospital

Active, not recruiting

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (CAR)

Soft Tissue Sarcoma | Gastric Cancer | Pancreatic Cancer | Solid Tumor | Bladder Cancer

China
Changhai Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma | Advanced Gastric Adenocarcinoma

China
Changhai Hospital
Rui Therapeutics Co., Ltd

Recruiting

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Sunshine Lake Pharma Co., Ltd.
Nicoya Therapeutics (Shanghai) Co., Ltd.

Not yet recruiting

HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia

Chronic Kidney Diseases | Renal Anemia

China
Sunshine Lake Pharma Co., Ltd.
Nicoya Therapeutics (Shanghai) Co., Ltd.

Not yet recruiting

Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.

Hemodialysis | Peritoneal Dialysis

China
Base Therapeutics (Shanghai) Co., Ltd.
Shanghai 10th People's Hospital

Enrolling by invitation

Safety and Efficacy of NK510 to Treat Gastric Cancer

Gastric Cancer

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in RRMM or PPCL

Multiple Myeloma | Primary Plasma Cell Leukemia

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
CARsgen Therapeutics Co., Ltd.
Shanghai East Hospital

Completed

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor

China
Karuna Therapeutics
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia (UNITE-001)

Schizophrenia

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Advance Non-small Cell Lung Cancer

Spain, Italy, Greece
Zhejiang Genfleet Therapeutics Co., Ltd.

Completed

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China, Australia
Zhejiang Genfleet Therapeutics Co., Ltd.

Active, not recruiting

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NSCLC, Stage III

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Large B-cell Lymphoma

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Completed

A Study of GFH018 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Completed

A Phase I Study of GFH312 in Healthy Chinese Subjects

Healthy Volunteer

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Withdrawn

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

Intermittent Claudication | Peripheral Artery Disease

United States
Zhejiang Genfleet Therapeutics Co., Ltd.

Withdrawn

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Solid Tumor
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Public Health Clinical Center

Active, not recruiting

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

Renal Cell Carcinoma

China
Asia Cell Therapeutics (Shanghai) Co., Ltd.
RenJi Hospital

Not yet recruiting

Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis

Ankylosing Spondylitis
Zhejiang University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
InventisBio Co., Ltd
InxMed (Shanghai) Co., Ltd.

Recruiting

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Solid Tumor

China
Shanghai YingLi Pharmaceutical Co. Ltd.
Shanghai HyaMab Biotech Co.,Ltd.

Not yet recruiting

A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Advanced Solid Tumors
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers

Healthy

China
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers

Healthy

China
InxMed (Shanghai) Co., Ltd.
InventisBio Co., Ltd

Recruiting

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Solid Tumor

China
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

CVL237 Tablets for APDS/PASLI

PI3K and P110delta Hyperactivation Syndrome

China
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations (CVL009-2001)

NSCLC

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer Recurrent

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

NSCLC

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Platinum-resistant Ovarian Cancer

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Metastatic Melanoma

United States, Australia
InxMed (Shanghai) Co., Ltd.

Completed

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Gastric Cancer

China
Hepagene (Shanghai) Co., Ltd.

Active, not recruiting

Phase 2a Study of HPG1860 in Subjects With NASH (RISE)

NASH - Nonalcoholic Steatohepatitis

United States
Shanghai Cingularbio Co. Ltd

Completed

Cingularbio® Heart Valve Clincial Study

Diseases of Mitral and Aortic Valves

China, Belgium, Poland
Hepagene (Shanghai) Co., Ltd.

Completed

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

Healthy

United States
Shanghai GeneChem Co., Ltd.

Unknown

A Study of GPC3 Redirected Autologous T Cells for Advanced HCC (GPC3-CART)

Carcinoma, Hepatocellular

China

Clinical Trials Sponsored by SHANGHAI RONA Therapeutics Co.,Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations